Nilotinib Pharos

Nilotinib, the active ingredient in Nilotinib Pharos, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively targets BCR‑ABL kinase and is used to treat chronic myeloid leukemia in adult patients. GNH USA supplies Nilotinib Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib acts on the BCR‑ABL tyrosine‑kinase pathway, providing disease control in chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and improves hematologic response. - Accelerated phase CML: helps achieve cytogenetic and molecular responses when disease progresses. - Blast phase CML: offers disease control in patients refractory to other tyrosine‑kinase inhibitors.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness. - Elevated lipase or amylase: may indicate pancreatic irritation. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - QT interval prolongation: can lead to serious cardiac arrhythmias. - Pancreatitis: severe abdominal pain with elevated enzymes. - Hepatotoxicity: significant elevation of liver transaminases. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or anaphylaxis.

Nilotinib requires careful monitoring and specific safety measures before and during therapy. - Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation. - Liver function: assess hepatic enzymes before initiation and during treatment. - Blood glucose: monitor fasting glucose as hyperglycemia may occur. - Pregnancy contraindication: avoid use in pregnant or nursing women; effective contraception is required. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nilotinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and risk QT prolongation. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce efficacy by lowering drug exposure. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem): may require dose adjustment. - H2‑blockers (e.g., ranitidine): can modestly affect nilotinib absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for muscle toxicity.